Six Months of Bedrolite: Enough to Buy Time, Not Enough to Build On

The email arrived this week in the inboxes of families who had spent weeks not knowing whether a medicine their children depend on would simply run out. Target Healthcare, a Glasgow-headquartered manufacturer that produces Bedrolite oil at its Durham facility, confirmed it holds enough stock to cover the next six months — a window of relative certainty in what has otherwise been a deeply uncertain few months for UK medical cannabis patients.

The relief is real. But six months is not a solution. It is a countdown.

How Bedrolite Ended Up in Durham

Bedrolite is a cannabidiol-based oil originally produced by Bedrocan, the Dutch state-licensed cannabis producer whose bankruptcy earlier this year sent shockwaves through the European medical cannabis supply chain. The oil is used primarily by patients with treatment-resistant epilepsy, including children, for whom there is often no clinically equivalent alternative.

Target Healthcare's involvement predates Bedrocan's collapse. Following disruption caused by Brexit, the company entered a technology transfer agreement with Transvaal Apotheek in The Hague in 2022, taking over Bedrolite production at its Durham site. The arrangement was confirmed in the UK Parliament in March 2022 by then-Health Minister Maria Caulfield. Under the agreement, Target produced batches in the UK that were sent back to the Netherlands for quality-control comparison against the Dutch reference product, with Transvaal's quality assurance lead visiting Durham reportedly five or six times to train staff and ensure consistency.

The result is an unusual supply architecture: a British manufacturer, using plant material from a Dutch facility now in bankruptcy proceedings, regulated by the Dutch Office of Medicinal Cannabis (OMC) — which must approve any transfer of that material under the Dutch Opium Act — and supplying patients under UK licensing rules set by the Medicines and Healthcare products Regulatory Agency (MHRA).

Three Routes Forward, None Yet Confirmed

According to reporting by Business of Cannabis, which first broke the details of Target's confirmation to patient families, there are three realistic paths to a longer-term supply arrangement — and none of them is yet confirmed as actively in motion.

The first is diplomatic: pressure is growing on the Dutch Ministry of Health to grant a time-limited export waiver modelled on the one Dutch authorities issued in 2021, which permitted pharmacies to continue supplying Bedrolite to the UK while domestic production was being established. Bedrocan's founder and former chairman, Tjalling Erkelens, has publicly backed this approach.

The second path runs through the bankruptcy process itself. A buyer could emerge from either the Dutch bankruptcy proceedings or the parallel Danish rekonstruktion who is both willing and able to continue the supply relationship with Target under a fresh OMC licence. That requires the right buyer, at the right price, with the right regulatory approvals — a narrow set of conditions.

The third option is the most structurally ambitious: standing up production of the specific Bedrocan plant material somewhere else in Europe. Bedrocan's head of corporate and marketing, Femke Starrenburg, has previously confirmed this would take at least six months even at Bedrocan's own Danish facility — meaning it could not resolve the current gap within the buffer window Target has just described.

Meanwhile, End Our Pain's Joanne Griffiths has stated in a letter to the UK Prime Minister that a licensed UK pharmaceutical company has signed an agreement with Bedrocan to manufacture, test, and arrange dispensing of Bedrolite and Bedica oils domestically. Business of Cannabis was unable to independently confirm the arrangement, and it is understood to face the same OMC licensing constraint as other supply routes.

What This Means Beyond the UK

The Bedrocan situation is not simply a post-Brexit supply chain problem, though Brexit undeniably complicated it. It is a structural warning about what happens when a single state-licensed producer sits at the centre of a medical cannabis supply chain spanning multiple jurisdictions, and then fails.

For European patients and regulators watching from elsewhere on the continent — including in Malta, where adult-use and medical cannabis operate under distinct frameworks, and where access to specialist medicines requires its own careful navigation — the Bedrocan collapse illustrates a risk that diversified, multi-producer pharmaceutical supply chains are designed to prevent. Medical cannabis, despite its growing clinical acceptance, is still often sourced from a handful of licensed producers with few redundancies built in.

The six-month buffer Target Healthcare has secured is a genuine act of commitment to its patient community, and the company's continued discussions with Bedrocan and other organisations suggest it is not treating this as the end of its responsibilities. But the three structural routes to a durable solution each depend on variables — Dutch regulatory decisions, bankruptcy auction outcomes, new cultivation timelines — that Target cannot control from Durham.

Patient organisations and MPs are applying pressure on both the UK and Dutch governments to treat this as the public health emergency it is. Whether that pressure produces a diplomatic waiver before the six months expire is, for now, the question that matters most.

Six months of certainty is better than none. Whether it proves to be enough time to build something lasting depends on decisions that have not yet been made in The Hague.

Featured image: Photo by Oliver King on Pexels